Concepts (279)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tandem Mass Spectrometry | 18 | 2024 | 182 | 5.670 |
Why?
|
| Chromatography, High Pressure Liquid | 16 | 2024 | 421 | 2.580 |
Why?
|
| Ovarian Neoplasms | 13 | 2015 | 312 | 1.700 |
Why?
|
| Chromatography, Liquid | 11 | 2023 | 142 | 1.630 |
Why?
|
| Rats | 25 | 2023 | 3483 | 1.350 |
Why?
|
| Rats, Sprague-Dawley | 16 | 2021 | 1618 | 1.210 |
Why?
|
| Polymorphism, Single Nucleotide | 10 | 2021 | 767 | 1.200 |
Why?
|
| Nicotinic Acids | 3 | 2013 | 8 | 1.040 |
Why?
|
| Reproducibility of Results | 13 | 2023 | 935 | 1.010 |
Why?
|
| Solvents | 2 | 2015 | 99 | 0.960 |
Why?
|
| Animals | 32 | 2023 | 15081 | 0.950 |
Why?
|
| Genetic Predisposition to Disease | 10 | 2015 | 628 | 0.930 |
Why?
|
| Biological Availability | 6 | 2021 | 88 | 0.870 |
Why?
|
| Pyridazines | 2 | 2013 | 14 | 0.820 |
Why?
|
| Microsomes, Liver | 1 | 2022 | 70 | 0.820 |
Why?
|
| Propolis | 1 | 2021 | 3 | 0.810 |
Why?
|
| Weightlessness | 1 | 2021 | 16 | 0.760 |
Why?
|
| Flavonoids | 1 | 2021 | 87 | 0.760 |
Why?
|
| Neoplasms, Glandular and Epithelial | 6 | 2015 | 40 | 0.740 |
Why?
|
| Gastrointestinal Tract | 1 | 2021 | 61 | 0.730 |
Why?
|
| Stilbenes | 2 | 2021 | 44 | 0.700 |
Why?
|
| Mannose | 3 | 2017 | 25 | 0.650 |
Why?
|
| Anti-Bacterial Agents | 1 | 2021 | 352 | 0.600 |
Why?
|
| Serum | 1 | 2016 | 15 | 0.580 |
Why?
|
| Antineoplastic Agents | 5 | 2022 | 803 | 0.560 |
Why?
|
| Reverse Transcriptase Inhibitors | 2 | 2013 | 57 | 0.530 |
Why?
|
| Proline | 2 | 2015 | 43 | 0.510 |
Why?
|
| Solubility | 4 | 2021 | 118 | 0.510 |
Why?
|
| Indoles | 1 | 2016 | 158 | 0.510 |
Why?
|
| Glucuronides | 3 | 2023 | 11 | 0.490 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2015 | 110 | 0.470 |
Why?
|
| Pyrrolidinones | 1 | 2013 | 7 | 0.470 |
Why?
|
| Matrix Metalloproteinases | 1 | 2013 | 48 | 0.460 |
Why?
|
| Drug Stability | 5 | 2018 | 116 | 0.460 |
Why?
|
| Administration, Oral | 3 | 2021 | 224 | 0.450 |
Why?
|
| Blood Coagulation | 1 | 2013 | 23 | 0.440 |
Why?
|
| Ovary | 1 | 2013 | 108 | 0.440 |
Why?
|
| Esophageal Neoplasms | 1 | 2014 | 127 | 0.440 |
Why?
|
| Male | 21 | 2021 | 20025 | 0.430 |
Why?
|
| Curcumin | 1 | 2013 | 74 | 0.430 |
Why?
|
| Warfarin | 1 | 2013 | 64 | 0.420 |
Why?
|
| Anticoagulants | 1 | 2013 | 102 | 0.420 |
Why?
|
| Antipyrine | 1 | 2012 | 3 | 0.410 |
Why?
|
| Hindlimb Suspension | 1 | 2012 | 14 | 0.410 |
Why?
|
| Menthol | 1 | 2012 | 21 | 0.410 |
Why?
|
| Mycophenolic Acid | 2 | 2023 | 7 | 0.410 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2012 | 48 | 0.400 |
Why?
|
| Microsomes | 2 | 2022 | 52 | 0.400 |
Why?
|
| Neoplasms | 2 | 2022 | 1103 | 0.390 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2012 | 121 | 0.380 |
Why?
|
| Chemistry, Pharmaceutical | 3 | 2015 | 71 | 0.360 |
Why?
|
| Humans | 30 | 2022 | 37093 | 0.360 |
Why?
|
| Methylcellulose | 1 | 2009 | 6 | 0.350 |
Why?
|
| Isoxazoles | 1 | 2009 | 11 | 0.350 |
Why?
|
| Half-Life | 3 | 2015 | 54 | 0.340 |
Why?
|
| Sucrose | 1 | 2009 | 26 | 0.340 |
Why?
|
| Anticonvulsants | 1 | 2009 | 34 | 0.340 |
Why?
|
| Nanoparticles | 3 | 2022 | 318 | 0.340 |
Why?
|
| Nicotine | 1 | 2012 | 257 | 0.340 |
Why?
|
| Drug Compounding | 1 | 2009 | 76 | 0.330 |
Why?
|
| alpha-Tocopherol | 1 | 2008 | 27 | 0.320 |
Why?
|
| Delayed-Action Preparations | 2 | 2013 | 60 | 0.310 |
Why?
|
| Vitamin A | 1 | 2008 | 87 | 0.310 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2008 | 63 | 0.300 |
Why?
|
| Female | 24 | 2021 | 20969 | 0.300 |
Why?
|
| Genetic Variation | 3 | 2015 | 387 | 0.300 |
Why?
|
| Vitamins | 1 | 2008 | 94 | 0.290 |
Why?
|
| Risk | 5 | 2015 | 267 | 0.290 |
Why?
|
| Nonprescription Drugs | 1 | 2006 | 5 | 0.290 |
Why?
|
| Niacin | 1 | 2006 | 22 | 0.280 |
Why?
|
| Genome-Wide Association Study | 4 | 2015 | 333 | 0.280 |
Why?
|
| Linear Models | 4 | 2021 | 275 | 0.260 |
Why?
|
| MicroRNAs | 1 | 2010 | 426 | 0.260 |
Why?
|
| Plasma | 2 | 2022 | 31 | 0.250 |
Why?
|
| Glycosides | 1 | 2024 | 21 | 0.240 |
Why?
|
| Nanospheres | 2 | 2014 | 7 | 0.240 |
Why?
|
| Sensitivity and Specificity | 2 | 2023 | 562 | 0.230 |
Why?
|
| Alleles | 3 | 2021 | 321 | 0.230 |
Why?
|
| Hydrogen Sulfide | 1 | 2023 | 39 | 0.230 |
Why?
|
| Phenols | 1 | 2024 | 80 | 0.230 |
Why?
|
| Mice | 8 | 2023 | 5913 | 0.230 |
Why?
|
| Biological Transport | 2 | 2021 | 185 | 0.210 |
Why?
|
| Glucuronidase | 1 | 2022 | 15 | 0.210 |
Why?
|
| Odds Ratio | 4 | 2015 | 534 | 0.210 |
Why?
|
| Middle Aged | 9 | 2017 | 10129 | 0.210 |
Why?
|
| Genotype | 6 | 2015 | 730 | 0.210 |
Why?
|
| Time Factors | 3 | 2012 | 1742 | 0.210 |
Why?
|
| Glucosides | 1 | 2021 | 16 | 0.200 |
Why?
|
| Fenoldopam | 1 | 2021 | 1 | 0.200 |
Why?
|
| Nitriles | 2 | 2013 | 69 | 0.200 |
Why?
|
| Honey | 1 | 2021 | 13 | 0.200 |
Why?
|
| Magnesium Hydroxide | 1 | 2021 | 1 | 0.190 |
Why?
|
| Antacids | 1 | 2021 | 2 | 0.190 |
Why?
|
| Bismuth | 1 | 2021 | 3 | 0.190 |
Why?
|
| Antidiarrheals | 1 | 2021 | 3 | 0.190 |
Why?
|
| Aluminum Hydroxide | 1 | 2021 | 7 | 0.190 |
Why?
|
| Salicylates | 1 | 2021 | 9 | 0.190 |
Why?
|
| Metabolic Clearance Rate | 1 | 2021 | 25 | 0.190 |
Why?
|
| Case-Control Studies | 6 | 2017 | 1130 | 0.190 |
Why?
|
| Weightlessness Simulation | 1 | 2021 | 21 | 0.190 |
Why?
|
| Genetic Association Studies | 3 | 2015 | 114 | 0.190 |
Why?
|
| Pyrimidines | 2 | 2013 | 118 | 0.190 |
Why?
|
| Drug Combinations | 1 | 2021 | 98 | 0.190 |
Why?
|
| Risk Factors | 6 | 2015 | 3562 | 0.190 |
Why?
|
| Aminopyridines | 1 | 2020 | 15 | 0.190 |
Why?
|
| Drug Interactions | 1 | 2021 | 141 | 0.190 |
Why?
|
| Aged | 7 | 2017 | 6741 | 0.180 |
Why?
|
| Organometallic Compounds | 1 | 2021 | 73 | 0.180 |
Why?
|
| Gene Frequency | 1 | 2021 | 195 | 0.180 |
Why?
|
| Oxyquinoline | 1 | 2020 | 5 | 0.180 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2021 | 83 | 0.180 |
Why?
|
| Tongue | 1 | 2019 | 11 | 0.180 |
Why?
|
| Communicable Diseases | 1 | 2020 | 45 | 0.170 |
Why?
|
| Tissue Distribution | 4 | 2023 | 207 | 0.170 |
Why?
|
| Pharmaceutical Solutions | 2 | 2015 | 5 | 0.160 |
Why?
|
| Chloroquinolinols | 1 | 2018 | 3 | 0.160 |
Why?
|
| Quantitative Trait Loci | 2 | 2015 | 77 | 0.160 |
Why?
|
| Enzyme Inhibitors | 1 | 2020 | 433 | 0.150 |
Why?
|
| Protein Binding | 3 | 2015 | 972 | 0.150 |
Why?
|
| Temperature | 2 | 2009 | 286 | 0.150 |
Why?
|
| Polyethylene Glycols | 2 | 2014 | 84 | 0.140 |
Why?
|
| Rats, Inbred F344 | 3 | 2021 | 245 | 0.140 |
Why?
|
| Colonic Polyps | 1 | 2017 | 67 | 0.140 |
Why?
|
| Adenoma | 1 | 2017 | 89 | 0.140 |
Why?
|
| Molecular Structure | 3 | 2024 | 492 | 0.130 |
Why?
|
| Area Under Curve | 2 | 2014 | 88 | 0.130 |
Why?
|
| Copper Radioisotopes | 1 | 2015 | 8 | 0.130 |
Why?
|
| Phototherapy | 1 | 2015 | 19 | 0.130 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2015 | 35 | 0.130 |
Why?
|
| Veratrum Alkaloids | 1 | 2015 | 2 | 0.130 |
Why?
|
| Lutetium | 1 | 2015 | 2 | 0.130 |
Why?
|
| Blood Proteins | 1 | 2015 | 66 | 0.130 |
Why?
|
| Adult | 7 | 2017 | 11712 | 0.130 |
Why?
|
| DNA, Neoplasm | 1 | 2015 | 92 | 0.130 |
Why?
|
| Radioisotopes | 1 | 2015 | 16 | 0.130 |
Why?
|
| Radiopharmaceuticals | 1 | 2015 | 55 | 0.130 |
Why?
|
| Gonadotropins | 1 | 2014 | 27 | 0.130 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2015 | 48 | 0.130 |
Why?
|
| Anilides | 1 | 2014 | 28 | 0.130 |
Why?
|
| Species Specificity | 1 | 2015 | 245 | 0.130 |
Why?
|
| Positron-Emission Tomography | 1 | 2015 | 80 | 0.120 |
Why?
|
| BRCA2 Protein | 1 | 2015 | 37 | 0.120 |
Why?
|
| Cyclohexanes | 1 | 2014 | 30 | 0.120 |
Why?
|
| Bilirubin | 1 | 2014 | 17 | 0.120 |
Why?
|
| BRCA1 Protein | 1 | 2015 | 48 | 0.120 |
Why?
|
| Liver | 2 | 2021 | 479 | 0.120 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2015 | 70 | 0.120 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2015 | 364 | 0.120 |
Why?
|
| Endometriosis | 1 | 2015 | 73 | 0.120 |
Why?
|
| Cell Line, Tumor | 4 | 2015 | 2231 | 0.120 |
Why?
|
| Itraconazole | 1 | 2013 | 12 | 0.120 |
Why?
|
| Polysorbates | 1 | 2013 | 10 | 0.120 |
Why?
|
| Injections, Intramuscular | 1 | 2013 | 20 | 0.120 |
Why?
|
| Antibodies | 1 | 2014 | 141 | 0.120 |
Why?
|
| Polyglycolic Acid | 1 | 2013 | 37 | 0.120 |
Why?
|
| Treatment Outcome | 3 | 2014 | 1369 | 0.110 |
Why?
|
| Fibroblast Growth Factors | 1 | 2013 | 33 | 0.110 |
Why?
|
| Neoplasm Proteins | 1 | 2015 | 213 | 0.110 |
Why?
|
| Head and Neck Neoplasms | 1 | 2014 | 78 | 0.110 |
Why?
|
| Pancreatic Neoplasms | 1 | 2015 | 111 | 0.110 |
Why?
|
| Hepatocyte Nuclear Factor 1-beta | 1 | 2013 | 2 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2013 | 10 | 0.110 |
Why?
|
| Acetaminophen | 1 | 2013 | 27 | 0.110 |
Why?
|
| Carrier Proteins | 1 | 2015 | 305 | 0.110 |
Why?
|
| Lactic Acid | 1 | 2013 | 95 | 0.110 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2015 | 807 | 0.110 |
Why?
|
| Biotransformation | 1 | 2013 | 67 | 0.110 |
Why?
|
| Adenocarcinoma | 1 | 2015 | 251 | 0.110 |
Why?
|
| Hydrolysis | 1 | 2013 | 99 | 0.110 |
Why?
|
| Survival Analysis | 1 | 2013 | 325 | 0.110 |
Why?
|
| Drug Carriers | 1 | 2013 | 125 | 0.110 |
Why?
|
| Reference Standards | 2 | 2013 | 52 | 0.110 |
Why?
|
| Drug Synergism | 1 | 2013 | 177 | 0.110 |
Why?
|
| Gold | 1 | 2014 | 136 | 0.110 |
Why?
|
| Radioimmunoassay | 1 | 2012 | 65 | 0.100 |
Why?
|
| Antifungal Agents | 1 | 2013 | 148 | 0.100 |
Why?
|
| Administration, Inhalation | 1 | 2012 | 80 | 0.100 |
Why?
|
| Cotinine | 1 | 2012 | 43 | 0.100 |
Why?
|
| Risk Assessment | 2 | 2015 | 753 | 0.100 |
Why?
|
| Colorectal Neoplasms | 1 | 2017 | 441 | 0.100 |
Why?
|
| Ethanol | 1 | 2013 | 192 | 0.100 |
Why?
|
| Models, Animal | 1 | 2012 | 134 | 0.100 |
Why?
|
| Metal Nanoparticles | 1 | 2014 | 183 | 0.100 |
Why?
|
| Kinetics | 1 | 2013 | 708 | 0.100 |
Why?
|
| Metabolomics | 3 | 2017 | 81 | 0.100 |
Why?
|
| Ribonucleoproteins, Small Nuclear | 1 | 2010 | 12 | 0.100 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2010 | 11 | 0.100 |
Why?
|
| Lymphokines | 1 | 2010 | 13 | 0.100 |
Why?
|
| Biosynthetic Pathways | 1 | 2010 | 13 | 0.100 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2010 | 26 | 0.100 |
Why?
|
| Early Detection of Cancer | 1 | 2014 | 336 | 0.090 |
Why?
|
| Epigenesis, Genetic | 1 | 2013 | 219 | 0.090 |
Why?
|
| Lung Neoplasms | 1 | 2014 | 358 | 0.090 |
Why?
|
| Haplotypes | 1 | 2010 | 182 | 0.090 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2010 | 132 | 0.090 |
Why?
|
| Refrigeration | 1 | 2009 | 4 | 0.090 |
Why?
|
| Drug Storage | 1 | 2009 | 27 | 0.090 |
Why?
|
| Transfection | 1 | 2010 | 523 | 0.090 |
Why?
|
| Disease Models, Animal | 1 | 2014 | 1371 | 0.090 |
Why?
|
| Suspensions | 1 | 2009 | 46 | 0.080 |
Why?
|
| Binding Sites | 1 | 2010 | 651 | 0.080 |
Why?
|
| Sex Factors | 1 | 2012 | 898 | 0.080 |
Why?
|
| gamma-Tocopherol | 1 | 2008 | 19 | 0.080 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 2008 | 98 | 0.080 |
Why?
|
| Smoking | 1 | 2014 | 940 | 0.080 |
Why?
|
| Mice, Inbred C57BL | 2 | 2021 | 1609 | 0.070 |
Why?
|
| Monosaccharides | 1 | 2024 | 11 | 0.060 |
Why?
|
| Aged, 80 and over | 1 | 2010 | 2379 | 0.060 |
Why?
|
| Breast Neoplasms | 1 | 2015 | 1502 | 0.060 |
Why?
|
| Feeding Behavior | 1 | 2008 | 454 | 0.060 |
Why?
|
| Mice, Nude | 2 | 2015 | 337 | 0.060 |
Why?
|
| Sulfides | 1 | 2023 | 62 | 0.060 |
Why?
|
| Methanol | 1 | 2023 | 18 | 0.060 |
Why?
|
| Mice, Inbred BALB C | 2 | 2015 | 661 | 0.060 |
Why?
|
| Swine | 1 | 2023 | 184 | 0.060 |
Why?
|
| Logistic Models | 2 | 2017 | 923 | 0.060 |
Why?
|
| Doxorubicin | 1 | 2022 | 84 | 0.050 |
Why?
|
| Glucuronates | 1 | 2021 | 6 | 0.050 |
Why?
|
| Liposomes | 1 | 2022 | 118 | 0.050 |
Why?
|
| Sulfates | 1 | 2021 | 23 | 0.050 |
Why?
|
| Glucuronosyltransferase | 1 | 2021 | 25 | 0.050 |
Why?
|
| Intestines | 1 | 2021 | 64 | 0.050 |
Why?
|
| Limit of Detection | 1 | 2021 | 59 | 0.050 |
Why?
|
| Feces | 1 | 2021 | 111 | 0.050 |
Why?
|
| Piperidines | 1 | 2021 | 77 | 0.050 |
Why?
|
| Hydrazones | 1 | 2020 | 5 | 0.050 |
Why?
|
| Drug Delivery Systems | 1 | 2022 | 202 | 0.050 |
Why?
|
| Chemistry, Physical | 1 | 2020 | 45 | 0.050 |
Why?
|
| Macaca fascicularis | 1 | 2020 | 64 | 0.050 |
Why?
|
| Mass Spectrometry | 1 | 2020 | 260 | 0.040 |
Why?
|
| Thermodynamics | 1 | 2020 | 216 | 0.040 |
Why?
|
| Heart | 1 | 2020 | 180 | 0.040 |
Why?
|
| Age Factors | 1 | 2021 | 1033 | 0.040 |
Why?
|
| Hypoxanthine | 1 | 2017 | 2 | 0.040 |
Why?
|
| Xanthine | 1 | 2017 | 3 | 0.040 |
Why?
|
| Intestinal Polyps | 1 | 2017 | 4 | 0.040 |
Why?
|
| Kidney | 1 | 2020 | 337 | 0.040 |
Why?
|
| Caffeine | 1 | 2017 | 28 | 0.040 |
Why?
|
| Urea | 1 | 2017 | 41 | 0.040 |
Why?
|
| United States | 1 | 2006 | 4223 | 0.030 |
Why?
|
| Nuchal Cord | 1 | 2015 | 1 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 583 | 0.030 |
Why?
|
| 3-Hydroxybutyric Acid | 1 | 2015 | 4 | 0.030 |
Why?
|
| Hep G2 Cells | 1 | 2015 | 51 | 0.030 |
Why?
|
| Morbidity | 1 | 2015 | 91 | 0.030 |
Why?
|
| Signal Transduction | 2 | 2014 | 1908 | 0.030 |
Why?
|
| Injections, Intralesional | 1 | 2014 | 11 | 0.030 |
Why?
|
| Heterozygote | 1 | 2015 | 93 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2015 | 77 | 0.030 |
Why?
|
| Disease Progression | 1 | 2017 | 601 | 0.030 |
Why?
|
| Homeodomain Proteins | 1 | 2015 | 132 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2015 | 148 | 0.030 |
Why?
|
| Genes, Reporter | 1 | 2015 | 136 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2014 | 150 | 0.030 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2014 | 16 | 0.030 |
Why?
|
| Genetic Markers | 1 | 2014 | 142 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2015 | 306 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2014 | 122 | 0.030 |
Why?
|
| DNA, Single-Stranded | 1 | 2014 | 37 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 2013 | 62 | 0.030 |
Why?
|
| Freeze Drying | 1 | 2013 | 27 | 0.030 |
Why?
|
| Texas | 1 | 2015 | 324 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2014 | 259 | 0.030 |
Why?
|
| Nanomedicine | 1 | 2013 | 35 | 0.030 |
Why?
|
| Nuclear Proteins | 1 | 2015 | 307 | 0.030 |
Why?
|
| Ligands | 1 | 2014 | 349 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 214 | 0.030 |
Why?
|
| Nanotechnology | 1 | 2014 | 153 | 0.030 |
Why?
|
| Prognosis | 1 | 2015 | 739 | 0.030 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2014 | 178 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2014 | 1492 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2015 | 681 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2013 | 515 | 0.020 |
Why?
|
| Mutation | 1 | 2015 | 1095 | 0.020 |
Why?
|
| DNA Methylation | 1 | 2013 | 325 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2015 | 2026 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2013 | 626 | 0.020 |
Why?
|
| Young Adult | 1 | 2015 | 4268 | 0.020 |
Why?
|
| Adolescent | 1 | 2015 | 5363 | 0.010 |
Why?
|